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Significance for public health 
Parkinson’s disease is the second most common neurodegenerative disorder affecting high 
number of the population. The achieved clinical results and disease control depending on early 
patients’ diagnostic and treatment. This study emphasizes on medicines utilization and most 
often used treatment approaches on Parkinson’s disease management. In addition, this is the first 
study exploring medicines utilization in Bulgaria. The findings reveal real medicines utilization 
in Bulgaria during 2018-2019 and its comparison with those found in the other countries. 
Regardless development of new therapies, levodopa-containing products reveals the highest rate 
of utilization as in most of the compared countries as in Bulgaria. 
	  
Abstract 
Background: Parkinson’s disease (PD), which occurs in 1% of the population, is the second most 
common neurodegenerative disorder. Despite the broad spectrum of PD manifestations and high 
disease prevalence, there are insufficient data on medicine utilization and prescription strategies. 
The purpose of the current study was to analyze published data concerning treatment approaches 
and to compare them with Bulgarian therapeutic practice.  
	  
	  
	  
Design and methods: We conducted a systematic review of the PubMed and Google Scholar 
databases, and we calculated medicine utilization in Bulgaria during 2018 and 2019 using the 
WHO methodology.  
Results: The literature search identified a total of 311 publications, but only 12 met the inclusion 
criteria. Eleven studies pointed out that levodopa-containing medicine are the most frequently 
used, followed by dopamine agonists. The highest rate was found for levodopa-containing 
products and decarboxylase inhibitor (1.06 and 1.33 DDD/1000 inh/day), followed by 
anticholinergic Biperiden (0.494 and 0.455 DDD/1000 inh/day) during 2018 and 2019 in 
Bulgaria. 
Conclusion: Overall, the treatment approaches used in the last decade comply with guideline 
recommendations, despite variations in levodopa and dopamine agonist utilization. Even though 
new medicines have been approved for PD management, levodopa-containing products are still 
most often prescribed and used worldwide. 
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Introduction 
 Parkinson’s disease (PD) is the second most common neurodegenerative disorder. About 
6.1 million individuals suffered from Parkinson’s disease in 2016; in 1990, it was 2.5 million1. 
Parkinson’s disease is one of the most common diseases in the population after 60 years of age 
and affects men more often than women 2. 
 The cause of PD remains unknown. It could be a result of the interaction between genetic 
and environmental factors that act upon fundamental cellular processes. There are no treatments 
that slow the degeneration 3. PD has been explained as a paradigmatic movement disorder 
determined by the presence of bradykinesia plus at least one additional motor function disorder 
during rest, tremor, rigidity, and impaired postural reflexes4. Neuropathological diagnosis 
requires dopaminergic neuron loss in the substantia nigra (SN), leading to more than 80% 
deficiency of striatal DA5. Clinical PD manifestations include asymmetric resting tremor, 
rigidity, bradykinesia, and non-motor symptoms (NMS), which include autonomic dysfunction, 
sleep disorders, and sensory and neuropsychiatric features. Despite a lack of cure for Parkinson's 
disease, a large number of medicines are available for the management of motor and nonmotor 
	  
	  
	  
symptoms6.Novel drugs should cover dopaminergic neuroprotection to reduce neurodegeneration 
and improve dopaminergic neurotransmission7. 
  The study identified 145 registered and ongoing clinical trials for therapeutics targeting 
PD, with 57 trials focused on long-term disease-modifying therapies, and the remaining 88 trials 
focused on therapies for symptomatic relief 8. A large number of therapies are currently being 
tested in clinical trials, including new approaches depending on disease cause, complications, or 
level of hepatotoxicity and antihypoxic activity of new molecules 9,10,11. 
 Despite the high disease prevalence, there are limited data regarding medicine utilization 
and prescription strategies in Bulgaria. There are 15,150 PD patients receiving medication 
therapy in the country; however, its cost is 20th out of total reimbursed expenditures 12.This fact 
prompted our interest to examine medicine utilization in Bulgaria and to compare the results with 
those found in other countries.  
 
Design and Methods 
Study design 
Systematic review of literature data 
 A retrospective search of available published data on medicine utilization and prescribed 
treatment regimens was conducted. The data on the most often prescribed or used medicines for 
the treatment of PD have been compared. A prisma flow diagram for the literature search was 
used to present complete information regarding study identification and selection. The systematic 
review aimed to collect evidence on all studies presenting the utilization patterns of anti-
Parkinson medication. 
 
Utilization of PD medicines in Bulgaria 
 The medicine utilization for Bulgaria has been calculated retrospectively using the WHO 
methodology to establish the trend of utilization and settled prescription patterns in PD 
management.  
 A total of nine international nonproprietary name (INN) monoproducts and combinations 
(ATC code N04) reimbursed in Bulgaria and included in the Positive Drug List (PDL) were 
observed from January 2018 to December 2019. The medicine utilization in DDD/1000 inh/day 
	  
	  
	  
is calculated according to WHO formulas used for defined daily dose (DDD) calculation based 
on annual sales data per INN within a country 13: 
DDD/1000 inh/day = ((sales data of reimbursed medicines in mg/DDD)/ (N inhabitants*365))× 
1000 
 
Data collection and analysis 
Systematic review of literature data 
 The first part of the study was a systematic review of published studies in thePubMed and 
Google Scholar databases. The used key words are "utilization of anti-Parkinson drugs" or 
"prescribing pattern in Parkinson disease" or "prescribing trend in Parkinson disease”. 
 The search encompassed a 10-year period from 2010 to 2020. To be considered for this 
review, studies had to meet the following inclusion criteria: 1) Clinical Trial, Meta-Analysis, 
Randomized Controlled Trial, Review, or Systematic Review concerning humans; 2) provide 
data for prescribing or utilization of medicines for PD, even if the abstract is published in 
English. There were no restrictions with regard to disease stage or patient characteristics. Despite 
the different approaches used in the observed studies, the main inclusion criteria require both 
data on prescribing or utilization and the range of medicines used in management of PD. Studies 
exploring complications of treatment, comorbidity, and disease epidemiology were excluded.  
 
Utilization of PD medicines in Bulgaria 
Sales data were collected from the National Health Insurance Fund (NHIF) database 12. 
Available data are used for calculation of utilization only of reimbursed-by-NHIF medicines, 
which does not cover the overall antiparkinsonian medicine market.  
DDD of the observed medicines was extracted from the World Health Organization 
database14. The number of inhabitants in Bulgaria was selected from National Statistical Institute 
(NSI) database, which showed the population in 2018 to be 7,000,039.00 people, whereas in 
2019 it is 6,951,482 15.  
Medicine utilization for each individual INN was calculated in DDD/1000 
inhabitants/day, revealing the most frequently used medicines for PD in Bulgaria during 2018 
and 2019. 
 
	  
	  
	  
Results 
Systematic review of published data about medicines utilization and prescription 
 A literature search identified311 publications screened for eligibility. After title and 
abstract screening, 92 articles were left for full-text screening. When abstracts concerning 
disease epidemiology, treatment recommendations, and management of complications were 
excluded, we found 22 studies concerning medicine prescription and utilization. Finally, we 
identified only 12 studies that met the inclusion criteria,in which the real data on trends of 
prescription and consumption were published. 
A flow diagram of the literature search is presented in Figure 1. The published data providing 
information on medicine utilization or prescribing trends are summarized in Table 1. 
There are limited data regarding drug utilization and its measurement. Overall, 12 studies 
explored prescribing trends and the utilization of medicines in Parkinson’s disease management. 
The diversity of the published data and methodologies in the included studies did not allow 
comparison of prescription or utilization of all groups of medicines used for PD therapy. In total, 
nine studies observed the trend by measuring medicines prescribed, whereas three studies were 
based on the WHO methodology for calculation of DDD/1000 inh/day. This fact makes 
comparison difficult, and only the final trend considering medicine rating could be compared.  
Eleven studies pointed out that levodopa-containing medicines are the most frequently 
prescribed or used, followed by dopamine agonists. Studies measuring the prescription of 
levodopa-containing products reveal that it covers the highest market share of the anti-Parkinson 
medicine market.  
 The percentage of prescriptions varies between 19.7% (as levodopa is the third most 
prescribed medicine in Japan) and 94%, as found in Germany. 
 
Utilization of medicines for treatment of PD in Bulgaria 
 Medicines forthe management of PD are reimbursed for both inpatient and outpatient 
treatment in Bulgaria. The reimbursed value paid by NHIF for hospital treatment is 100%, 
whereas for ambulatory treatment, medicines are reimbursed at either 75% or 100% (except for 
Rasagiline, which is reimbursed at 25%), which supposes that they are affordable for patients. 
According to the mechanism of action, the reimbursed products are divided into the following 
	  
	  
	  
groups: dopa and dopa derivatives, dopamineagonists, anticholinergics (tertiaryamines, ethers, 
chemically related to antihistamines, ethers of tropicortropin derivatives), MAO-B inhibitors, 
amantidine derivatives, and drugs with other mechanisms of action.  
 A reviewof utilization calculated in DDD/1000 inh/day shows the highest rate of 
utilization of products containing levodopa and decarboxylase inhibitors and triple levodopa-
containing combinations (1.06and 1.33 DDD/1000 inh/day) inBulgaria, followedby 
anticholinergic Biperiden (0.494 and 0.455 DDD/1000 inh/day) and MAO-B inhibitor selegiline 
(0.462 and 0.357  DDD/1000 inh/day) during 2018 and 2019. 
 The utilization of the newer product rasagaline is still low, despite a slight increase in 
2019. It is higher than the utilization of older and well-established products such as apomorphine 
and similar to that of pramipexole (Figure 3). 
Discussion 
 A report in Italy revealed that benserazide and levodopa (0.7-0.8), as well as carbidopa 
and levodopa (0.7-0.9) DDD/1000 inh/ day, followed by pramipexole (0.1-0.4) and biperidene 
(0.4-0.5), were the most prescribed medicines between 2000 and 2008 29. Similar results were 
published by the Finnish Medicines Agency, revealing the highest utilization rates for levodopa 
and decarboxylase inhibitor (between 1.58-1.56 DDD/1000 inh/ day during 2016 and 2018), and 
levodopa, decarboxylase inhibitor, and COMT inhibitor (0.70-0.72 DDD/1000 inh/day) during 
2016–2018 30. 
 According to the European Physiotherapy Guideline for PD, symptomatic relief 
recommendations are based mainly on the utilization of the dopamine precursor levodopa and 
dopamine agonists. Levodopa treatment results in rigidity, tremor, and bradykinesia. In addition 
to levodopa, dopamine agonists are prescribed for other complications, such as restless legs 
syndrome, sleep fragmentation, and akinesia or dystonia. Over the past decade, treatment 
strategieshave revealed that initial therapy with an agonist is well-tolerated, and levodopa could 
be added later if symptoms worsened. Dopamine agonists are prescribed in the early stages of the 
disease, preferably in young people who are more prone to developing motor complications later. 
MAO-B inhibitors are used in the early disease stage or as an adjuvant to levodopa for motor 
complication control. Relief of motor complications could be achieved after increasing the dose 
	  
	  
	  
of levodopa,use of COMT or MAO-B inhibitors, addition of apomorphine (to reduce the 
duration and frequency of unpredictable off-states) and amantadine, and intraduodenal levodopa 
(for unpredictable motor complications). Once the disease has progressed, deep-brain stimulation 
using a pacemaker is useful, which mimics the effect of the lesion without destroying brain 
tissue31. 
 The National Institute for Health and Care Excellence (NICE) guidelines of the United 
Kingdom suggest that initial treatment of early motor symptoms should include levodopa, 
dopamine agonists, or MAO-B inhibitors for people in the early stages of Parkinson’s disease 
whose motor symptoms do not affect their quality of life. The treatment regimen should be based 
on levodopa if a patient's quality of life is affected. The addition of dopamine agonists, MAO-B 
inhibitors, or catechol-O-methyl transferase (COMT) inhibitors as adjuncts to levodopa is 
recommended for people with Parkinson's disease who have developed dyskinesia or motor 
fluctuations despite optimal levodopa therapy. When symptoms are not adequately controlled by 
medical therapy for patients with advanced Parkinson's disease, deep-brain stimulation is 
recommended 32. 
 A Japanese study investigated adherence to the 2011 Japanese guidelines33 for the 
treatment of Parkinson’s disease (PD) in real-life practice. The results revealed that the highest 
number of patients (49.6%) received levodopa (L-dopa) monotherapy, followed by non-ergot 
dopamine agonists (DA) prescribed as monotherapy (8.3%) or levodopa (8.1%). Inconsistent 
with the guidelines, levodopa monotherapy was the most prescribed drug in patients between 51 
and 69 years of age. The prescription of levodopa monotherapy and non-ergot DA monotherapy 
decreased in the span of 4 years, whereas those of combination therapy including levodopa and 
non-ergot DA increased. Nearly 75% of patients started initial treatment within 13 days of 
diagnosis. Levodopa monotherapy is the most frequently prescribed medicine for the treatment 
of patients older than 70 years, consistent with the guidelines. The article concluded that PD 
treatment in Japan followed most of the recommendations in the 2011 national guidelines. 
 The treatment of Parkinson's disease in Bulgaria is performed by specialized neurological 
commissions according to the National Consensus for Diagnosis and Treatment of PD adopted 
and updated by the Bulgarian Society of Neurology at the end of 2018. Therapeutic approaches 
are similar to those of other countries and depend on the severity and progression of the disease. 
	  
	  
	  
Prescription of levodopa-containing medicines at minimal effective doses is recommended in the 
advanced stages of disease. If motor and non-motor complications appear, combination therapy 
is preferred, whereas in the final disease stages, deep-brain stimulation or levodopa/carbidopa 
intestinal gel pump therapy, both paid by public funds in Bulgaria, may be used34. 
 The utilization of anti-Parkinson medicines in Bulgaria is similar to that found in other 
countries. The results reveal that the utilization of levodopa-containing medicines in the country 
was the highest in both 2018 and 2019. This is almost twice as highas that of biperiden. On the 
other hand, dopamine agonists are the second-most prescribed medicines in most studies. 
However, their consumption in Bulgaria is lower than that in other countries. The study also 
found that rasagaline utilization remains very low, significantly lower than that of selegiline 
(0.224 vs. 0.462 DDD/1000 inh/day). This could be a result of differences in prices, despite 
similar clinical characteristics. Another study in Italy also found that higher rasagiline utilization 
leads to an increase in both overall treatment costs and PD-related costs 35. 
 The main guideline recommendations include approaches based on dopamine agonist 
utilization, preferably for younger patients and those with relatively mild symptoms. The 
established high rate of prescription and utilization of dopamine agonists suggests that they are a 
preferable choice for patients as initial treatment if the disease has not progressed yet. 
 Limited knowledge about the mechanisms of neurodegeneration in PD and the 
heterogeneity of the pathology are the main challenges in the field of neurology. New diagnostic 
methods, gene therapy 36,non-dopaminergic strategy for neuroprotection, xanthine derivatives 
research37,38, approaches for antagonism of adenosine A2A receptors, monoamine oxidase type-
B inhibition (MAO-B) 39, 40, and deep-brain stimulation 41are promising tools for achieving better 
clinical results in disease management.  
 To the best of our knowledge, this is the first study toinvestigate the use of medicines for 
the management of PD in Bulgaria and compares the results with those published in other 
countries. As PD is the second most common neurodegenerative disorder affecting older people, 
preferred treatment approaches in relation to established recommendations are crucial. This can 
provide data on the overall prevalence and progression of the disease, as well as a review of 
currently used treatment regimens. 
	  
	  
	  
 A limitation of our study is that we used data on prescribing and utilization to define 
overall medicine consumption. We recognize that these are different methods, and not all 
prescribed medicines could be assessed as consumed. As there is limited data measuring 
utilization alone, we consider that our results based on prescription are relevant to evaluate the 
trend in medicine consumption and development of prescribing approaches.  
 
Conclusions 
 The overall treatment approaches used within the last decade comply with the guideline 
recommendations. We found some variations in levodopa and dopamine agonist utilization from 
country to country. Despite the high number of new medicines approved for PD management, 
levodopa-containing products are still the most frequently prescribed and used medicines in 
Bulgarian recent years. 
 The limited published data exploring medicine prescribing and utilization reveal that 
further studies are needed to confirm this conclusion. 
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Table 1. Publications concerning measuring or comparing of medicine 
utilization/prescription in PD. 
Authors Type of the study Publication objective Main results 
Kalilani et al., 
201917 
Retrospective cohort 
study 
The goal of the studyis to describe treatment 
patterns in patients newly diagnosed with 
Parkinson’s disease (PD) in the United States 
(US) and the United Kingdom (UK) during 
2004–2015. The study includes 11,280 
patients from IBM MarketScan database and 
7775 patients in CPRD who fulfilled the 
inclusion criteria. 
- Levodopa was the most frequently 
prescribed first-line medication(US: 
70.1%, UK: 29.0%).  
-  57.9% of patients in the US and 
23.8% in the UK remained on the 
first monotherapy treatment till the 
end of the study. 
Orayj et al., 
201918 
Systematic literature  
review 
A review identifies all studies measuring 
prescribing patterns between 1967 and 
2017. Of the 44 studies, 35 explore the 
prescribing pattern with or without 
measuring prescribing determinants, and 9 
studies measured the prescribing 
determinants and 
factors affecting utilization. 
-Levodopais the most commonly 
prescribed medicine, accounting for 
46.50% to 100% of all prescriptions 
for PD 
- prescription level of ergot-derived 
DAs in several countries decreased 
(due to cardiac toxicity issues) 
-prescription level of non-ergot DAs 
increased 
- The prescribing rates of COMT 
inhibitors, MAO-B inhibitors, 
amantadine, and anticholinergics 
reveal significant country-to-country 
variation.  
Möller et al, 
200519 
Nationwide 
questionnaire survey 
A nationwide survey of sudden onset of 
sleep (SOS) in patients with PD was 
initiated among the members of the German 
patient support group (deutsche Parkinson–
Vereinigung, dPV). This study analyzes 
data sets from more than 6,500 PD patients 
in order to establish most frequently 
administered drugs. 
The most frequently administered 
drugs were: 
- levodopa (94.2 %),  
-dopamine agonists (DA) (71.7 %): 
- amantadine (40.1 %),  
-selegiline (27.6 %), 
- entacapone (20.4 %), 
- budipine (12.3 %), 
- anticholinergics (11.8 %). 
Machado-Alba  
et al.,201820 
Descriptive cross-
sectional study 
Study determines the prescribing patterns of 
antiparkinson drugs and the variables 
associated with its use in Colombia. A total 
of 2,898 patients was included between 
January 1st and March 31st, 2015. 
The most frequently prescribed 
medicines: - levodopa 45.5%, where 
the most commonly used 
combinations includes levodopa/ 
carbidopa and entacapone 
- biperiden 23.1%,  
-amantadine 18.3% 
-pramipexole 16.3%. 
Shah J et al, 
2019 21 
Observational cross-
sectional study  
The aim of the study is to assess drug 
utilization pattern and quality of life in 
patients of Parkinson’s Disease. 40 patients 
with PD of at least 1 month duration and 20 
age-based controls were analyzedin a span of 
The most frequently prescribed 
medicines: - levodopa and carbidopa 
combinations (45%) 
- dopamine agonists (18%),  
-anticholinergic drugs (15%), 
	  
	  
	  
8 weeks from April 2018 to July 2018 - amantadine (12%),  
- MAO inhibitors (5%)  
- COMT inhibitors (5%).  
Nakaoka  et al., 
201422 
Analyzing of 
prescribing trends of 
anti-Parkinson drugs 
The study describes the prescribing trends 
during 2005 - 2010 in Japan, and examined 
whether these trends changed after the drug 
safety measures in 2007. The analysis used 
medical claim data from January 2005 to 
December 2010 for patients older than 30 
years using anti-Parkinson drugs. 
The most frequently prescribed 
medicines: - Levodopa(2005- 58%; 
2010- 51%)  
- prescription level ofergot dopamine 
agonists decreased 
-prescription level ofnon-ergot 
dopamine agonists increased after 
2007 
Kakariqi L et al, 
201723 
Retrospective analysis 
of utilization using 
DDD methodology 
The study analyzes utilization of anti-
Parkinsonian drugs in Albania using the 
Anatomic Therapeutic Chemical 
Classification-Defined Daily Dose 
(ATC/DDD methodology) along with 
morbidity comparison for the period 2004-
2014. Data were assembled from the Health 
Insurance Institute. 
The most frequently utilized 
medicines: 
- combination of levodopa with 
benserazide0.47-0.75 DDD/1000 
inhabitants/day  
- combination of levodopa with 
carbidopa is 0.04-0.29 DDD/1000 
inhabitants/day  
- Dopamine receptor agonists are not 
included in the reimbursement 
scheme. Total consumption (period 
2004-2014) is 1.45 - 1.53 DDD/1000 
inhabitants/day. 
Kasamo S et al, 
201924 
Retrospective 
descriptive overview 
of real-world 
prescribing data 
Descriptive study using the Japanese 
medical claims database to describe the 
epidemiology and real-world 
pharmacological treatment patterns of 
newly diagnosed patients with young-onset 
Parkinson's disease. All included patients 
were newly diagnosed between 1, 2005 and  
March 31, 2016. 
 The most frequently prescribed 
medicines: 
- Dopamine agonists (49.2%) were 
most commonly prescribed initially 
-anticholinergics (23.8%),  
-levodopa (19.7%),  
-and others (4.1%).  
The levodopa equivalent daily dose 
increased steadily with longer 
disease duration.  
Gaida et al, 
201425 
Retrospective drug 
utilization review 
The aim of the study is to analyze the 
treatment of Parkinson’s disease through 
cross-sectional, retrospective study 
conducted on prescription data for 2010 in 
South Africa. The total number of analyzed 
products is 25,523 prescribed to 5,168 
patients. 
The most frequently prescribed 
medicines: 
-Levodopa-containing products 
46.50% 
-Dopamine agonists (pramipexole 
and ropinirole) 39.80%  
- anticholinergic agents (9.20%),  
- MAO-B inhibitor selegiline 
(2.12%)  
- amantadine (1.80%). 
Pitcher et al, 
2014 26 
Retrospective data 
utilization analysis 
Measuring of antiparkinsonian agent 
utilization in the outpatient community in 
New Zealand using the national prescription 
database for the period 1995–2011. The 
The most frequently utilized 
medicines: 
-Levodopa(0.78-1.38 DDD/1000 
inh/day),  
	  
	  
	  
study uses the number of defined daily 
doses per 1000 inhabitants per day for 
calculation of utilization. 
-Benzotropineanticholinergics (1.11-
0.59), 
- Selegiline MAO B inhibitor (0.59-
0.11) 
Increases in the dispensed volumes 
of levodopa (77%), amantadine 
(350%), and catechol-o-methyl 
transferase inhibitors (326%) 
occurred during the study period.  
Crispo et al., 
201527 
Population-based 
cohort study 
 Standardized (age, sex, race, and census 
region) annual prevalence of antiparkinson 
drug use, trends, and polypharmacy by age 
and sex between January 2001 and 
December 2012 in the USA 
The most frequently prescribed 
medicines: 
-levodopa (85%)  
- dopamine agonists (28%) 
Hollingworth et 
al, 201128 
Retrospective data 
utilization analysis 
Examines trends in the prescribing of anti-
Parkinsonian drugs (APD) in Australia from 
1995 to 2009 
- levodopa + carbidopa - 0.76-0.82 
DDD/1000 population/day  
- levodopa + benserazide - 0.34 to 
0.55 DDD/1000 population/day 
- levodopa + carbidopa + entacapone 
-0.03-0.10 (between 2005-2009 
  
	     
	  
	  
	  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
	  
Figure 1. Prisma flow diagram of the literature search and process of study selection, adapted 
from the PRISMA statement.19 
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Figure 2. Percentage of levodopa prescription from overall antiparkinson medicine 
market. 
 
 
 
 
 
Figure 3. Antiparkinson medicine utilization in DDD/1000 inh/day during 2018 and 2019.   
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